C4 Therapeutics, Inc.
CCCC
Rank in Stocks
#13482
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on... C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
Share Price
$3.15
Last synced: 2026-11-09
Market Cap
$387.53M
Change (1 day)
1.61%
Change (1 year)
27.02%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade C4 Therapeutics, Inc. (CCCC)
Category
Healthcare
Operating Margin for C4 Therapeutics, Inc. (CCCC)
Operating Margin as of November 2026 TTM: -318.97%
According to C4 Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -318.97%. At the end of 2025 the company had an operating margin of -290.68%.
Operating Margin history for C4 Therapeutics, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -318.97% | 9.73% |
| 2025 | -290.68% | -13.53% |
| 2024 | -336.15% | -49.82% |
| 2023 | -669.84% | 60.80% |
| 2022 | -416.56% | 132.21% |
| 2021 | -179.39% | -1.49% |
| 2020 | -182.10% | 9.82% |
| 2019 | -165.81% | 95.90% |
| 2018 | -84.64% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.12% |
US
|
|
| -149.01% | -99.53% |
US
|
|
| 25.57% | -100.08% |
AU
|
|
| 31.23% | -100.10% |
BE
|
|
| 29.35% | -100.09% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about C4 Therapeutics, Inc.'s operating margin
What is C4 Therapeutics, Inc.'s operating margin?
C4 Therapeutics, Inc.'s operating margin is -318.97%, as of Nov 2026.
What was C4 Therapeutics, Inc.'s operating margin in 2025?
In 2025, C4 Therapeutics, Inc.'s operating margin was -290.68%, compared with -336.15% in 2024.
How has C4 Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, C4 Therapeutics, Inc.'s operating margin was highest in 2021 (-179.39%) and lowest in 2023 (-669.84%).
How does C4 Therapeutics, Inc.'s operating margin compare with similar companies?
C4 Therapeutics, Inc.'s operating margin (-318.97%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.